Role of Bispecific Antibodies in Multiple Myeloma

In this segment on relapsed multiple myeloma, Luciano Costa asks Carol Ann Huff to discuss the evolving role of bispecific antibodies within the treatment landscape. Dr. Huff highlights that bispecific antibodies, particularly those targeting BCMA, have emerged as an important therapeutic option for patients with relapsed disease, offering meaningful response rates even in heavily pretreated populations. She notes that clinicians are increasingly considering how these agents may be integrated earlier in the disease course, especially for patients with limited options due to prior therapy exposure. When differentiating among available and emerging bispecific therapies, key considerations include target selection, efficacy outcomes such as depth and durability of response, safety profiles including risks of cytokine release syndrome and infection, as well as practical factors such as dosing schedules and monitoring requirements. Overall, the discussion emphasizes the growing clinical relevance of bispecific antibodies in multiple myeloma and the need to individualize treatment decisions based on patient and disease characteristics.